史美倫:疫情推動醫療科技發展 相信本港生科行業發展只屬起步
港交所(00388.HK)主席史美倫出席生物科技峰會2021時表示,香港已成為亞洲最大及全球第二大生物科技公司上市樞紐,在上市宗數、集資規模及板塊市值的增長率均為全球最高。但她認為只屬發展起步階段,相信未來幾年生物科技及醫療保健將繼續成為市場主要增長引擎,有助鞏固香港金融中心地位。
她指出,自2018年實施上市新規,允許未盈利生物科技公司來港上市,為其連接國際資本及投資者,推動快速增長,至今已有逾250家生物科技公司在港上市,港府亦給予眾多支持,疫情更是促使市民加強關注醫療保健,市場進一步採用線上醫療保健及數據分析,以及更多公私營合作研發疫苗及治療方案等。
她透露,首七個月香港IPO集資額按年增長85%,至今保持全球新股集資額第三位,國際貨幣基金組織於6月初認可香港金融體系有抵禦金融衝擊及危機能力,未來將致力拓寬市場廣度及深度,提升競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.